296 related articles for article (PubMed ID: 37790928)
1. Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy.
Shebbo S; Binothman N; Darwaish M; Niaz HA; Abdulal RH; Borjac J; Hashem AM; Mahmoud AB
Front Immunol; 2024; 15():1350208. PubMed ID: 38533510
[TBL] [Abstract][Full Text] [Related]
2. Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment.
He X; Lan H; Jin K; Liu F
Front Immunol; 2023; 14():1237764. PubMed ID: 37790928
[TBL] [Abstract][Full Text] [Related]
3. Colorectal Cancer Immunotherapy: Options and Strategies.
Johdi NA; Sukor NF
Front Immunol; 2020; 11():1624. PubMed ID: 33042104
[TBL] [Abstract][Full Text] [Related]
4. T-cell immunoglobulin and ITIM domain, as a potential immune checkpoint target for immunotherapy of colorectal cancer.
Fathi M; Pustokhina I; Kuznetsov SV; Khayrullin M; Hojjat-Farsangi M; Karpisheh V; Jalili A; Jadidi-Niaragh F
IUBMB Life; 2021 May; 73(5):726-738. PubMed ID: 33686787
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study.
Lin T; Song C; Chuo DY; Zhang H; Zhao J
Tumour Biol; 2016 Apr; 37(4):4367-72. PubMed ID: 26499782
[TBL] [Abstract][Full Text] [Related]
6. [Looking back 2018--focused on colorectal cancer].
Cai J; Wang L
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):9-16. PubMed ID: 30703787
[TBL] [Abstract][Full Text] [Related]
7. The potential role of immunotherapy to treat colorectal cancer.
Amin M; Lockhart AC
Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
[TBL] [Abstract][Full Text] [Related]
8. Intratumor heterogeneity and cell secretome promote chemotherapy resistance and progression of colorectal cancer.
Källberg J; Harrison A; March V; Bērziņa S; Nemazanyy I; Kepp O; Kroemer G; Mouillet-Richard S; Laurent-Puig P; Taly V; Xiao W
Cell Death Dis; 2023 May; 14(5):306. PubMed ID: 37142595
[TBL] [Abstract][Full Text] [Related]
9. Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape.
Mulet-Margalef N; Linares J; Badia-Ramentol J; Jimeno M; Sanz Monte C; Manzano Mozo JL; Calon A
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831367
[TBL] [Abstract][Full Text] [Related]
10. Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer.
Ros J; Balconi F; Baraibar I; Saoudi Gonzalez N; Salva F; Tabernero J; Elez E
Front Oncol; 2023; 13():1112276. PubMed ID: 36816981
[TBL] [Abstract][Full Text] [Related]
11. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives.
Baulu E; Gardet C; Chuvin N; Depil S
Sci Adv; 2023 Feb; 9(7):eadf3700. PubMed ID: 36791198
[TBL] [Abstract][Full Text] [Related]
12. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
[TBL] [Abstract][Full Text] [Related]
13. The crosstalk between the gut microbiota and tumor immunity: Implications for cancer progression and treatment outcomes.
Wang M; Zhang L; Chang W; Zhang Y
Front Immunol; 2022; 13():1096551. PubMed ID: 36726985
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
